Publications

FREE AND LOW-COST PROSTATE CANCER SCREENING

FOR IMMEDIATE RELEASE
September 11, 2012
 

CONTACT:   Mollie Turner, JPA
(202) 591-4062
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

 

fREE AND lOW-COST PROSTATE CANCER SCREENING opportunities ACROSS THE cOUNTRY AIM TO IMPROVE EARLY DIAGNOSIS, SURVIVAL

Patient Group Highlights the Importance of Biomarkers as Part of
Annual Prostate Cancer Awareness Week (Sept. 16-22)

DENVER, CO – As the debate over the benefits of prostate cancer screening continues, new research reinforces that early testing and diagnosis are key to survival. A new study released in late August by the Journal of Urology shows there is value in prostate-specific antigen (PSA) testing, as men diagnosed and treated for prostate cancer lived longer during the time when PSA testing was widely recommended when compared to the pre-PSA testing era. In addition, another study reported in the New England Journal of Medicine shows a nearly 30 percent reduction in prostate-cancer mortality among men who underwent screening for prostate-specific antigen (PSA) levels.

To alert men to the dangers of prostate cancer and the importance of early detection, and to educate on innovations in screening options, the Prostate Conditions Education Council (PCEC)  holds an annual Prostate Cancer Awareness Week (PCAW). This year’s PCAW will be held the week of September 16. The goal of PCAW is to provide at-risk men in the U.S. with a free or low-cost opportunity to get tested for prostate cancer, and this year the PCEC expects more than 125,000 men will be screened. During PCAW, testing centers will be set up around the country where men can receive prostate screenings, along with other health assessments.

“As the research shows, countless lives could be saved if more men knew about the dangers of prostate cancer and took action to get tested,” explains Wendy Poage, MHA, president of the PCEC. “This year, nearly 30,000 American men will die from prostate cancer. That is just too many for a disease that is often treatable when caught early.”

During the past several years, researchers have introduced many exciting medical advances in prostate cancer testing, which mean improved and more accurate options for men. Biomarker tests, which identify a specific mark on person’s DNA for cancer, are helping men better understand their risk for developing the disease. They are also reducing unnecessary biopsies with more accurate readings and the re-testing of previously collected prostate tissues. Biomarker tests can also help to define an effective course of treatment for men with prostate cancer by distinguishing between aggressive and non-aggressive tumors and predicting survival rates.

As part of PCAW, PCEC is providing patients with more information about existing and expected biomarker tests on their website.

“While these scientific advancements can provide tremendous benefit, it’s also important for men to remember that a screening that shows an elevated PSA level is not a diagnosis,” said Poage. “And, with a prostate cancer diagnosis, immediate treatment is not always necessary. Sometimes active surveillance, or watchful waiting, can be the best course of action for a patient with a small, non-aggressive tumor.”

Keith Wegen, 45, of Broomfield, Colorado, knows well the value of prostate cancer screening. After not feeling his healthy and active self for several years, he was screened and diagnosed with prostate cancer in 2011. While his diagnosis was delayed because doctors considered him too young for prostate cancer, Wegen is now a survivor working to spread the word about the benefits of early testing.

“Early detection saved my life,” said Wegen. “More men need to know about their risk, and their opportunities to get screened. If I can save just one life through my efforts, I will have done my job.”

As a leading authority on prostate cancer, the PCEC recommends a prostate health assessment for all men beginning at 35 years of age, including PSA and digital rectal exam (DRE). The organization has detailed guidelines for men and their doctors for PSA monitoring, to help men avoid unnecessary biopsies and treatment. 

Screenings during PCAW takes approximately 10 minutes and includes a PSA blood test and DRE performed by a trained professional. Men also have the option to receive a cholesterol and testosterone level check, to promote overall health awareness and the evaluation of other prostate cancer risk factors. PCAW is one of the longest-running and most successful screening programs in history. To find a nearby PCAW screening site and for more information on prostate cancer, visit http://www.prostateconditions.org/screening-site or call toll free 866-4PROST8.

#   #   #

Men's Health Alliance - PCEC Partnership Announced

 

FOR IMMEDIATE RELEASE

Contact:

Scott Williams, Men’s Health Network
202-997-8065
 
Wendy Poage, Prostate Conditions Education Council
303-316-4685
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

 

Partnership Launches to Improve the Health and Wellbeing of

Men, Boys, and Their Families

 

Washington, DC, June 21, 2012 – Men’s Health Network and the Prostate Conditions Education Council announced the launch of a new partnership, Men’s Health Alliance. 

The goal of the Men’s Health Alliance, a global collaboration, is to advance the awarenss, advocay and education of men’s health.  Helping men, boys and families to take actionable steps in improving and managing their health and well being. The collaboration will allow the organizations to expand their reach to include even more men and boys, the women who care about them, healthcare professionals, key thought leaders, and other stakeholders in men’s health.

The collaboration will allow the two complimentary organizations to join forces, capitalize on each organizations strengths and enhance complimentary efforts, programs and goals including awareness and education programs centered around sporting events, workplaces and the faith-based community. 

“Our organizations are doing great work on their own, but together we can reach more men around the world, who can benefit from the valuable resources and services that we provide. We believe this partnership with Men’s Health Network is a positive step in moving the men’s health conversation from exclusively ‘below the belt’ to looking at the whole picture of men’s health,” stated Wendy Poage, President of Prostate Conditions Educational Council.

The Denver-based Prostate Conditions Education Council has the largest prostate cancer screening program in the country and hosts a series of 5k races and other awareness events throughout the year.

On average men live five years less than their female counterparts and are far less likely to make preventive health visits. Over 240,000 men are expected to be diagnosed with prostate cancer in 2012 and over 28,000 men will die from the disease.

Men’s Health Network, formed in 1992, is based in Washington, DC and led the efforts to sign National Men’s Health Week into law. Men’s Health Network works with places of worship, workplaces, legislators, government agencies, fatherhood initiatives, and health organizations across the country to raise awareness of the silent crisis in men’s health.

Scott Williams, Vice President of Men’s Health Network explained, “Men’s health in the United States is in a dire state. Working collaboratively with Prostate Conditions Education Council we can expand the reach of our awareness programs to include a much larger audience with the ultimate goal of helping men live longer, healthier, and happier lives.”

About Prostate Conditions Education Council

A national organization committed to men’s health, the Prostate Conditions Education Council (PCEC) is the nation’s leading resource for information on prostate health.  The PCEC is dedicated to saving lives through awareness and the education of men, the women in their lives, as well as the medical community about prostate cancer prevalence, the importance of early detection, and available treatment options, as well as other men’s health issues.  For more information, please visit www.prostateconditions.org.

About Men's Health Network

Men's Health Network (MHN) is a non-profit organization whose mission is to reach men, boys and their families where they live, work, play, and pray with health prevention messages and tools, screening programs, educational materials, advocacy opportunities and patient navigation. With a network of chapters, affiliates, and health partners, MHN has a presence in every state and over 30 countries.  For more information, please visit www.menshealthnetwork.org.M

FDA Approves Xtandi

FOR IMMEDIATE RELEASE

Contact:
Wendy Poage
303-725-5614
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

Prostate Conditions Education Council Applauds FDA Priority Review and Approval

Leading PROSTATE CANCER GROUP SAYS New drug GIVES HOPE TO MEN WITH ADVANCED prostate cancer

The Prostate Conditions Education Council (PCEC), applauds today’s approval by the United States Food and Drug Administration (FDA) of a groundbreaking new therapy, Xtandi. The drug has shown promise in clinical trials, extending the life of men with advanced prostate cancer even following other treatments. 

“This new therapy represents an important advancement in the treatment of prostate cancer, extending survival in patients who failed previous chemotherapy for castration-resistant disease,” said Daniel Petrylak, M.D., PCEC council member and director of the genitourinary oncology program and co-director of the signal transduction program at the Yale University Cancer Center.

The PCEC, a national organization committed to men’s health and a leader in supporting prostate cancer research and treatment, has been working for several decades to improve treatment options.  New treatments like Xtandi- an antiandrogen therapy that acts to block testosterone, slowing prostate cancer growth - are bringing new hope to men with prostate cancer.

"Since our work with antiandrogens began over two decades ago, we have been waiting for a superior agent that shows promise for late-stage patients; today we have it with the approval of Xtandi,” said E. David Crawford, M.D. head of the urologic oncology department at the University of Colorado Health Sciences Center, and founder/chairman of the PCEC.  “I am confident that this is only the beginning of success stories with this agent and that it will be used in earlier stages of prostate cancer in the near future.  While this therapy is an innovative development for patients in the late stages of prostate cancer, early detection and treatment are key to survival. Continued efforts to improve awareness and education of the disease are still very important and support efforts to diagnose and treat the disease before it reaches the advance stages.”

Prostate cancer remains the second leading cause of cancer death among American men[i], and can be an aggressive disease that is most successfully treated when detected early on. Each year, the PCEC holds Prostate Cancer Awareness Week, dedicated to offering free or low-cost screenings for more than 125,000 men across the U.S. and internationally. This year, the week is being held September 16-22.  Since the first PCAW in 1989, the program has helped to screen nearly five million men in the U.S., and this number continues to grow each year both at home and internationally.

About the Prostate Conditions Education Council

A national organization committed to men’s health, the Prostate Conditions Education Council (PCEC) is the nation’s leading resource for information on prostate health. The PCEC is dedicated to saving lives through awareness and the education of men, the women in their lives, as well as the medical community about prostate cancer prevalence, the importance of early detection, and available treatment options, as well as other men’s health issues. The Council – comprised of a consortium of leading physicians, health educators, scientists and prostate cancer advocates – aims to conduct nationwide screenings for men and perform research that will aid in the detection and treatment of prostate conditions. More information is available at www.prostateconditions.org. 

About Xtandi

Xtandi, formerly known as Enzalutamide or MDV3100,  is an oral, once-daily agent that is an androgen receptor signaling inhibitor. Xtandi inhibits androgen receptor signaling in three distinct ways: it inhibits 1) testosterone binding to androgen receptors; 2) nuclear translocation of androgen receptors; and 3) DNA binding and activation by androgen receptors. In the Phase 3 AFFIRM trial common side effects observed more frequently in Xtandi as compared with placebo-treated patients included fatigue, diarrhea and hot flush. Seizure was reported in less than 1% of Xtandi-treated patients. Serious adverse events, adverse events causing patients to stop treatment, and adverse events causing death all were lower in the Xtandi group than in the placebo group. 

# # #

 


[i] http://www.cdc.gov/cancer/dcpc/data/men.htm

 

New Prostate Screening Test FDA Approved

 

For Immediate Release:

June 25, 2012

Contact:         Wendy Poage
                      (303) 316-4685
                      This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

 

NEW SCREENING OPTION COMING FOR PROSTATE CANCER

Denver, CO -The Prostate Conditions Education Council (PCEC), a national organization committed to men’s health and a leader in prostate cancer screening, released the following statement in response to the Premarket Approval (PMA) from the United States Food and Drug Administration (FDA) for Beckman Coulter’s Prostate Health Index (phi).  The statement is attributed to PCEC President, Wendy Poage, MHA.

“Today’s announcement of Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for Beckman Coulter’s Prostate Health Index (phi) represents a promising and exciting advancement for men and their physicians.  As the debate around prostate cancer screening continues, the PCEC welcomes the addition of new screening tools that offer men options that improve upon current screening methods.  Our hope is that new options like this test will help to mitigate concerns around screening by reducing the number of unnecessary biopsies, cutting back on the over diagnosis and treatment of prostate cancer, and lowering costs associated with prostate cancer detection.  

Prostate cancer remains the second leading cause of cancer death among American men.[i]  Prostate cancer can be an aggressive disease that is most successfully treated when it is detected early on.  The PCEC believes all men should be informed about the disease and their options for testing.  Each year, the PCEC holds Prostate Cancer Awareness Week, dedicated to offering free or low-cost screenings for more than 125,000 men across the U.S. and internationally.  Since the first PCAW in 1989, the program has helped to screen nearly five million men in the U.S., and this number continues to grow each year both at home and internationally.”

About the Prostate Conditions Education Council

A national organization committed to men’s health, the Prostate Conditions Education Council (PCEC) is the nation’s leading resource for information on prostate health.  The PCEC is dedicated to saving lives through awareness and the education of men, the women in their lives, as well as the medical community about prostate cancer prevalence, the importance of early detection, and available treatment options, as well as other men’s health issues.  The Council – comprised of a consortium of leading physicians, health educators, scientists and prostate cancer advocates – aims to conduct nationwide screenings for men and perform research that will aid in the detection and treatment of prostate conditions.  More information is available at www.prostateconditions.org.  

 

 


 

[i] http://www.cdc.gov/cancer/dcpc/data/men.htm

BE BLUE Campaign

BE BLUE CAMPAIGN

Company Aims to Raise $10,000 to Benefit Prostate Conditions Education Council

CHICAGO, June 1, 2012 /PRNewswire/ -- Phusion Projects, LLC today announced the inaugural year of their philanthropic program, BE BLUE, which will benefit the Prostate Conditions Education Council (PCEC). Throughout the month of June, the company hopes to raise $10,000 for the organization whose mission is to "save and improve the lives of men and their loved ones in early detection, research, education and awareness for prostate cancer and all prostate conditions."

The newly launched BE BLUE program will challenge the employees of Phusion Projects to raise awareness and funds for PCEC by wearing various blue items throughout the month of June—Men's Health Month—to get people talking about prostate health assessments and prevention. Around 100 employees will be uploading pictures of themselves in their blue attire to the Phusion Projects Facebook page and the company has an internal competition between their East and West Coast divisions for pride and bragging rights.  The program is being piloted in 2012, with the goal of expanding it next year to include distributors and consumers in supporting the cause.

"One in six men will be diagnosed with prostate cancer in their lifetime, and Phusion Projects is dedicated to raising awareness for this issue in the hopes that more men will get screened for this type of cancer," said Chris Short, vice president of communications. "We encourage our employees to participate in a program that could likely impact someone they are close to. Our goal is to educate our employees about this important cause, and they in turn will raise awareness about BE BLUE and PCEC's vital mission."

"We are excited that Phusion Projects has selected the PCEC as the beneficiary of the BE BLUE program and appreciate their dedication and support," said Heidi Schuman, national race director for PCEC. "We look forward to piloting this program in 2012 and working with Phusion in the coming years."

For more information on our corporate initiatives, visit the Phusion Projects Facebook page.

About Phusion Projects

Phusion Projects, LLC is a Chicago-based alcoholic beverage company that sells its products – including Four Loko, Four MaXed, Earthquake and Moskato Life – nationwide.  From the company's inception, Phusion Projects has been committed to making contributions to communities, operating as a responsible member of the alcoholic beverage industry and setting unmatched standards in this regard. To learn more about Phusion Projects and its commitment to responsible drinking, please visit http://www.phusionresponsibility.com and http://www.phusionprojects.com. In addition, we encourage you to learn the facts about Four Loko at http://www.phusionprojects.com/factvsfiction.html.

About Prostate Conditions Education Council

A national organization committed to men's health, the Prostate Conditions Education Council (PCEC) is the nation's leading resource for information on prostate health.  The PCEC is dedicated to saving lives through awareness and the education of men, the women in their lives, as well as the medical community about prostate cancer prevalence, the importance of early detection, and available treatment options, as well as other men's health issues.  The Council – comprised of a consortium of leading physicians, health educators, scientists and prostate cancer advocates – aims to conduct nationwide screenings for men and perform research that will aid in the detection and treatment of prostate conditions.

PCEC organizes hundreds of free or low-cost screening sites annually for more than 125,000 men across the United States and internationally.  To date, the program has resulted in over 5 million prostate health assessments.

SOURCE Phusion Projects

Source: PR Newswire (http://s.tt/1daeS)

New Clinical Trial - Janssen Biotech, Inc

Prostate Conditions Education Council & Janssen Biotech, Inc.

Janssen Biotech, Inc. is sponsoring an advanced prostate cancer research study. This study will evaluate the effectiveness of an investigational drug plus prednisone to determine if there is a decrease in Prostate-Specific Antigen (PSA). The study will also evaluate whether this combination prolongs the time until it is evident that the cancer has spread. Additionally, safety information will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last. You may be eligible for the study if you:

  1. Are eighteen years of age or older
  2. Have been diagnosed with prostate cancer
  3. Are currently receiving, and have had continuous therapy with, Gonadotropin-releasing hormone (GnRH) monotherapy for at least 6 months or have undergone surgical removal of the testicles

To learn more about this study, please visit www.prostatecancerstudynow.com

 

 

Prostate Mapping Biopsy Impacting Treatment Decisions

Latest Technique for Prostate Cancer Dianosis Decreases Need for Prostatectomy

The diagnosis and treatment of prostate cancer (PCa) is currently undergoing a revolution similar to that seen over the past three decades with respect to the improvements made in breast cancer screening, diagnosis and treatment options.  The long-standing gold standard for PCa diagnosis is the Transrectal Ultrasound (TRUS) guided prostate needle biopsy.  While TRUS is still used to make an initial diagnosis, in recent years, the development of a staging prostate biopsy – the Transperineal 3D Mapping Biopsy – has been introduced, allowing physicians to better understand the stage and gravity of the cancer in order to make more informed treatment decisions.

Read more: Prostate Mapping Biopsy Impacting Treatment Decisions

Prostate Cancer Council Encourages Mens Health Practices at Screening Sites throughout the Country

Prostate Conditions Education Council Hosts 23rd Annual Prostate Cancer Awareness Week, September 16-22;  Program Prompts New International Initiative

As the most common cancer and second leading cause of cancer death among American men, it’s important to be aware of the resources currently available to detect prostate cancer.  While experts continue to explore the benefits of prostate cancer screenings, the Prostate-Specific Antigen (PSA) test and Digital Rectal Exam (DRE) remain the safest routes to detecting the disease in its earliest stages – when it’s most treatable.  

Read more: Prostate Cancer Council Encourages Mens Health Practices at Screening Sites throughout the Country

Prostate Conditions Education Council Opposes US Preventative Services Task Force Recommendation

Contact: Wendy Poage
President, Prostate Conditions Education Council
(303) 316-4685
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

Dana Conti
Jones Public Affairs
(617) 945-9316
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

The Prostate Conditions Education Council (PCEC) – a national organization committed to men’s health and a leader in prostate cancer screening – today announced it strongly opposes the newly released recommendations from the U.S. Preventative Services Task Force (USPSTF). The draft guidance recommends against prostate-specific antigen (PSA) screening for prostate cancer.

Read more: Prostate Conditions Education Council Opposes US Preventative Services Task Force Recommendation